Evidence map›Paper›PMID 42760540›Full record

ArticleInfectious diseases of poverty2026

Territorial inequities in access to essential medicines for neglected tropical diseases in a decentralised European health system: a nationwide assessment in Spain.

Moncef Belhassen-García, Fernando de la Calle-Prieto, José Manuel Del Moral Sánchez, Montserrat Alonso-Sardón, Blanca Ayuso-Garcia, Jose-Ramon Blanco, Cristina Bustos Morell, David Campany-Herrero, Cristina Carranza, Miren Ercilla Liceaga and 26 more

Abstract read
In one paragraph

Article in Infectious diseases of poverty, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Moncef Belhassen-GarcíaDepartment of Internal Medicine, Infectious Diseases Unit, Salamanca University Hospital, Biomedical Research Institute of Salamanca, Centre for Tropical Diseases Research, University of Salamanca, Salamanca, Spain. belhassen@usal.es.
Fernando de la Calle-PrietoNational Referral Unit for Imported Diseases and International Health, High Level Isolation Unit, IdiPAZ, La Paz-Carlos III University Hospital, CIBERINFEC, Madrid, Spain.
José Manuel Del Moral SánchezHospital Pharmacy Department, Vega Baja University Hospital, Orihuela, Spain.
Montserrat Alonso-SardónDepartment of Preventive Medicine and Public Health, University of Salamanca, Biomedical Research Institute of Salamanca, Centre for Tropical Diseases Research, University of Salamanca, Salamanca, Spain.
Blanca Ayuso-GarciaInfectious Diseases Unit, Lucus Augusti University Hospital, Lugo, Spain.
Jose-Ramon BlancoDepartment of Infectious Diseases, San Pedro Hospital, Logroño, Spain.
Cristina Bustos MorellHospital Pharmacy Department, Barbastro Hospital, Barbastro, Spain.
David Campany-HerreroPharmacy Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Cristina CarranzaUniversity Institute of Biomedical and Health Research, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Miren Ercilla LiceagaPharmacy Department, OSI Debabarrena, Basque Health Service, San Sebastián, Spain.
Milagros Garcia López-HortelanoVega Baja University Hospital, Orihuela, Spain.
Elisa García-VázquezDepartment of Clinical Medicine, Miguel Hernández University, Elche, Spain.
Beatriz GarridoDepartment of Clinical Medicine, Miguel Hernández University, Elche, Spain.
Michele Hernandez CabreraInfectious Diseases and Tropical Medicine Unit, Insular Maternal and Child University Hospital, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Carlos IberoDepartment of Infectious Diseases, Navarra University Hospital, Pamplona, Spain.
Aitziber Illaro UrangaPharmacy Department, Marqués de Valdecilla University Hospital, Santander, Spain.
Cristina Jimenez NúñezHospital Pharmacy Department, La Paz University Hospital, Madrid, Spain.
Xabier Kortajarena UrkolaDepartment of Infectious Diseases, Donostia University Hospital, Biogipuzkoa Health Research Institute, San Sebastián, Spain.
Julia LapeñaDepartment of Infectious Diseases, San Pedro Hospital, Logroño, Spain.
Jara Llenas-GarcíaVega Baja University Hospital, Orihuela, Spain.
Ana López-VizcaínoInfectious Diseases Unit, Lucus Augusti University Hospital, Lugo, Spain.
Irene Losada-GalvanBarcelona Institute for Global Health, Barcelona, Spain.
Paloma MerinoDepartment of Clinical Microbiology, Hospital Clínico San Carlos, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain.
Álvaro MorenoDepartment of Internal Medicine, Infectious Diseases Unit, Salamanca University Hospital, Biomedical Research Institute of Salamanca, Centre for Tropical Diseases Research, University of Salamanca, Salamanca, Spain.
Ana María MuletPharmacy Department, Virgen del Puerto Hospital, Extremadura Health Service, Plasencia, Spain.
Miriam NavarroMinistry of Health, Madrid, Spain.
Javier Pardo LledíasDepartment of Internal Medicine, Marqués de Valdecilla University Hospital, Santander, Spain.
Jose A Perez-MolinaNational Referral Centre for Tropical Diseases, Department of Infectious Diseases, Biomedical Research Networking Centre for Infectious Diseases, Carlos III Health Institute, Ramón y Cajal University Hospital, Madrid, Spain.
Leonor Periañez ParragaPharmacy Department, Son Espases University Hospital, Mallorca, Spain.
Gracia Picazo SanchísHospital Pharmacy Department, Castile-La Mancha Health Service, Ciudad Real, Spain.
Laura Pozo RosadoDepartment of Internal Medicine, Virgen del Puerto Hospital, Extremadura Health Service, Plasencia, Spain.
Julia Praena-SegoviaClinical Unit of Infectious Diseases, Microbiology and Parasitology, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocío University Hospital, CSIC/University of Seville, Seville, Spain.
Joaquín Salas-CoronasCIBERINFEC, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Fernando SalvadorCIBERINFEC, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Joaquín Urda-RomachoHospital Pharmacy Department, Poniente University Hospital, Almería, Spain.
María Romay-BarjaCIBERINFEC, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeglected tropical diseases (NTDs) represent an increasing but often overlooked challenge for European health systems owing to international mobility, migration, travel, and climate-related changes in disease ecology. Although effective treatments exist for most NTDs and many are included in the World Health Organization (WHO) Model List of Essential Medicines, their availability in decentralised high-income health systems remains poorly characterised. This study assessed the availability, accessibility, and territorial variability of essential medicines for NTDs across the autonomous communities of Spain and identified the main barriers to equitable access.

methodsA nationwide, cross-sectional study was conducted across the 17 autonomous communities of Spain. Data were collected between January and December 2025 through a structured survey of Hospital Pharmacy Services in centres with expertise in tropical medicine and infectious diseases and were complemented by expert clinical validation. Medicines were classified according to commercial status, access pathways, dispensing circuits, and regional availability. Descriptive analyses summarised inter-regional variability from a health systems and policy perspective.

resultsData were obtained for 63 medicines and vaccines, generating 1134 records from all 17 autonomous communities. Twenty-two medicines were commercially available in Spain, whereas 39 required exceptional access mechanisms. Routine stock availability across all centres was reported in only 31.1% of valid records, while 52.8% reported no routine stock and 16.1% restricted availability to reference centres. Joint management by prescribing physicians and hospital pharmacy services was required in 72.1% of access procedures. Marked territorial variability was also observed in dispensing circuits and financing mechanisms, with 47.9% of valid records requiring full out-of-pocket payment and 47.1% involving co-payment.

conclusionsAccess to essential medicines for NTDs in Spain remains structurally fragmented and territorially unequal. Strengthening coordinated national pharmaceutical policies is necessary to reduce reliance on exceptional access mechanisms and ensure equitable, timely, and sustainable access to essential medicines in Spain and other decentralised European health systems.

Indexed as

Drugs, EssentialHealth Services AccessibilityNeglected DiseasesTropical MedicineCross-Sectional StudiesHumansSpainDrugs, EssentialAccess to medicinesDecentralized health systemsEuropeHealth equityNeglected tropical diseasesPharmaceutical policy

Identifiers

PMID42760540
PMCPMC13587272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.